Miragen Therapeutics (NASDAQ: MGEN) is 110.46% higher on its value in year-to-date trading and has touched a low of $0.31 and a high of $2.47 in the current 52-week trading range. The MGEN stock was last observed hovering at around $1.01 in the recent trading session, with the current loss setting it -0.02% off its average median price target of $5.00 for the next 12 months. It is also 83.5% off the consensus price target high of $6.00 offered by analysts, but current levels are 75.25% higher than the price target low of $4.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
At last check, trading at $0.99, the stock is -9.93% and 12.35% above its SMA20 and SMA50 respectively. However, with a current trading volume of 0.56 million and changing -2.36% at the moment leaves the stock 31.86% off its SMA200. MGEN registered -52.80% loss for a year compared to 6-month gain of 84.44%. The firm has a 50-day simple moving average (SMA 50) of $0.9994 and a 200-day simple moving average (SMA200) of $0.7649.
The stock witnessed a 16.05% loss in the last 1 month and extending the period to 3 months gives it a 146.34%, and is -9.01% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.97% over the week and 14.91% over the month.
Miragen Therapeutics (MGEN) has around 45 employees, a market worth around $56.13M and $4.90M in sales. Distance from 52-week low is 217.11% and -60.07% from its 52-week high. The company has generated returns on investments over the last 12 months (-174.20%).
Miragen Therapeutics (MGEN) Analyst Forecasts
The EPS is expected to shrink by -20.90% this year.
Miragen Therapeutics (MGEN) Top Institutional Holders
32 institutions hold shares in Miragen Therapeutics (MGEN), with 3M shares held by insiders accounting for 5.66% while institutional investors hold 17.96% of the company’s shares. The shares outstanding are 53.08M, and float is at 46.88M with Short Float at 1.05%. Institutions hold 16.94% of the Float.
The top institutional shareholder in the company is FMR, LLC with over 3.89 million shares valued at $1.73 million. The investor’s holdings represent 7.33% of the MGEN Shares outstanding. As of Mar 30, 2020, the second largest holder is Atlas Venture Advisors, Inc. with 3.14 million shares valued at $1.4 million to account for 5.92% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 1.61 million shares representing 3.03% and valued at over $0.72 million, while Alyeska Investment Group, L.P. holds 1.40% of the shares totaling 0.74 million with a market value of $0.33 million.
Miragen Therapeutics (MGEN) Insider Activity
A total of 1 insider transactions have happened at Miragen Therapeutics (MGEN) in the last six months, with sales accounting for 0 and purchases happening 1 times.
Miragen Therapeutics (MGEN): Who are the competitors?
The company’s main competitors (and peers) include Quest Diagnostics Incorporated (DGX) that is trading 15.60% up over the past 12 months. Laboratory Corporation of America Holdings (LH) is -0.14% down on the 1-year trading charts. Short interest in the company’s stock has risen 29.65% from the last report on May 14, 2020 to stand at a total of 0.35 million short shares sold with a short interest ratio of 0.26.